查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1999322

生物製药CMO/CRO市场：2026-2032年全球市场预测（按产品类型、服务类型、治疗领域、应用和最终用户划分）

Biopharmaceutical CMO & CRO Market by Product Type, Service Type, Therapeutic Area, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，生物製药 CMO/CRO 市场价值将达到 1,137.4 亿美元，到 2026 年将成长至 1,352.5 亿美元，到 2032 年将达到 3,865.8 亿美元，复合年增长率为 19.09%。

主要市场统计数据
基准年 2025 1137.4亿美元
预计年份：2026年 1352.5亿美元
预测年份 2032 3865.8亿美元
复合年增长率 (%) 19.09%

清晰而有力地概述了日益复杂的治疗方案、监管要求和供应韧性如何重新定义全球 CMO 和 CRO 的策略重点。

随着治疗方案的复杂性、监管力度和商业化时间表的不断变化，策略重点也在不断重塑，契约製造（CMO）和合约研究（CRO）产业正经历着快速转型。外包不再只是降低成本的交易，它已成为加速创新、扩大产能以及在药物发现、开发和商业化的各个阶段分担风险的核心要素。生物製药、基因和细胞疗法以及模组化生产方法的日益复杂化，推动了对能够支持从分析测试到临床供应以及商业填充和包装等一体化工作流程的合作伙伴的需求。

识别技术、监管和商业性因素的融合，这些融合将从根本上改变 CMO 和 CRO 行业的服务交付模式和竞争优势。

契约製造和研发产业的格局正受到多项变革的重塑，这些变革并行发展，相互影响。首先，由于治疗方法的创新，技术复杂性日益增加。细胞疗法、基因疗法和先进生物製药的兴起需要新的製程技术、专业设施和训练有素的人员。因此，对生产能力的投资不仅要扩大规模，还要在严格的品质和安全标准下，加快迭代开发週期。

检验了近期关税政策和贸易趋势的变化如何加剧供应链风险，并迫使整个药品开发和製造外包流程进行策略重组。

影响关税和贸易流动的政策变化正对全球製造业和临床供应链产生重大影响，预计2025年生效或建议实施的关税措施的累积效应正在加速整个行业的战略重新评估。药品活性成分、一次性组件和专用设备的进口关税增加，推高了外包生产的总成本，并可能由于采购和海关程序的变化而略微延长前置作业时间。为此，许多申办者和供应商正在重新评估其供应商所在地，以平衡成本、前置作业时间确定性和监管合规性。

全面的细分洞察，将服务模式、产品复杂性、治疗应用和最终用户特征与策略能力要求和伙伴关係模式相匹配。

详细的細項分析揭示了服务类型、产品类型、治疗应用和最终用户群体中，能力、监管要求和商业性优先事项的交汇点。提供的服务包括分析工作流程、细胞培养操作、临床开发支援、填充和包装能力、製剂专业知识、临床前开发和製程开发。临床开发支持从I期到III期的各项活动，每个阶段都有其独特的监管要点和供应要求。产品类型分为大分子和小分子。大分子包括生物製药和生物相似药，其中生物製药涵盖单株抗体、重组蛋白和疫苗。小分子涵盖学名药和新化学实体（NCE），它们在进入临床试验的速度和製造地规模方面各有不同。

对美洲、欧洲、中东和非洲以及亚太生态系统中的设施投资、监管合规和合作伙伴选择具有区域战略意义。

地理环境在整个合约研发生产（CDMO）生态系统中，对产能投资、监管策略和商业部署都起着决定性作用。美洲地区拥有成熟的环境，其特点是法规结构完善、生物製药和先进治疗领域人才济济，以及大量私人和公共资本流入产能扩张领域，尤其是在物流和临床生态系统健全的地区。这种环境有利于能够利用涵盖研发、临床试验执行和商业供应的整合网路的申办者和供应商。

深入洞察技术深度、策略伙伴关係和数位化驱动的卓越营运如何重新定义医药研发和製造外包领域的领导地位。

服务供应商之间的竞争格局日益取决于其技术平台的深度、跨开发阶段的整合能力以及应对复杂治疗方法的敏捷性。主要企业透过投资专业设施、专有分析平台和自动化技术来降低变异性并加快出货前测试，从而实现差异化。同时，一些灵活的细节领域服务提供者正利用其特定专长，例如病毒载体生产、CAR-T细胞疗法或mRNA产品的先进填充和包装，提供灵活且以客户为中心的合约模式，吸引新兴生物技术赞助商。

为高阶主管提供可操作且优先考虑的建议，以增强整体外包开发和製造流程的营运韧性、监管合应对力和策略伙伴关係。

产业领导者应采取务实且优先的措施，以确保专案进度按计画进行、提高柔软性并保障商业性竞争力。首先，申办方和供应商需要加快对平台技术和模组化设施设计的投资，从而在不影响品质的前提下实现快速分子转移和可扩展生产。这包括对高影响力功能进行有针对性的资本投资，例如专用病毒载体设施、封闭式细胞疗法生产系统以及用于处理温度敏感製剂的先进填充和包装生产线。

我们采用严谨、透明、多方面的研究途径，结合高阶主管的访谈、技术咨询和第二手资料，为实务工作者提供见解和建议。

本研究采用多方面方法，旨在确保获得稳健且可重复的洞见，从而反映当前的行业趋势和从业者经验。该调查方法结合了对赞助商、供应商和机构相关人员相关方的高级管理人员进行的定性访谈，以及与工艺科学家、监管专家和供应链专家进行的技术咨询，以检验营运影响。这些对话的目的并非得出量化预测，而是为了了解关于产能限制、技术应用和伙伴关係模式的实际观点。

简明结论总结了对能力、监管合规和稳固伙伴关係的投资如何决定医药研发外包的长期竞争力。

整体情况，产业正处于转折点，科学创新、日益复杂的营运以及地缘政治趋势相互交织，重新定义了外包策略。那些有选择地投资于专业能力、数位化基础设施和弹性供应链网路的赞助商和供应商，将更有能力降低研发专案的风险，并加快患者获得治疗的速度。同样重要的是，要采用能够协调奖励并共同承担品质和进度责任的伙伴关係架构。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：生物製药CMO/CRO市场：依产品类型划分

  • 聚合物化合物
    • 生物製药
      • 单株抗体
      • 重组蛋白
      • 疫苗
    • 生物相似药
  • 低分子
    • 学名药
    • 新化学物质

第九章：生物製药CMO/CRO市场：依服务类型划分

  • 分析
  • 细胞培养
  • 临床开发
    • 第一阶段
    • 第二阶段
    • 第三阶段
  • 灌装/包装
  • 配方
  • 临床前开发
  • 製程开发

第十章：生物製药CMO/CRO市场：依治疗领域划分

  • 肿瘤学
  • 感染疾病
  • 循环系统
  • 中枢神经系统
  • 免疫学和炎症
  • 呼吸系统
  • 代谢/内分泌
  • 罕见疾病

第十一章：生物製药CMO/CRO市场：依应用领域划分

  • 细胞疗法
    • CAR T
    • 干细胞
  • 基因治疗
    • 非病毒
    • 病毒载体
  • 单株抗体
    • 双重特异性
    • 组合型
    • 不合格的
  • 重组蛋白
    • 酵素
    • 生长因子
    • 荷尔蒙
  • 疫苗
    • 失活
    • 活病毒疫苗
    • mRNA
    • 次单元

第十二章：生物製药CMO/CRO市场：依最终用户划分

  • 生技公司
    • 大型生技公司
    • 中小型生技公司
  • CRO
    • 全方位服务
    • 小众服务
  • 製药公司
    • 一级
    • 二级
    • 三级
  • 研究机构
    • 学术机构
    • 政府

第十三章：生物製药CMO/CRO市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：生物製药CMO/CRO市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：生物製药CMO/CRO市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国生物製药CMO/CRO市场

第十七章：中国生物製药CMO/CRO市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • AbbVie, Inc.
  • arexel International Corporation
  • Baxter International Inc.
  • Boehringer Ingelheim Biopharmaceuticals GmbH
  • Boehringer Ingelheim GmbH
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • Eurofins Scientific Limited
  • FUJIFILM Diosynth Biotechnologies USA, Inc.
  • ICON Plc
  • KBI Biopharma, Inc.
  • KEMWELL BIOPHARMA PRIVATE LIMITED
  • Laboratory Corporation of America Holdings
  • Lonza Group AG
  • NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC
  • Patheon Inc.
  • Rentschler Biopharma SE
  • Sterling Pharma Solutions
Product Code: MRR-3A2E844FDA5E

The Biopharmaceutical CMO & CRO Market was valued at USD 113.74 billion in 2025 and is projected to grow to USD 135.25 billion in 2026, with a CAGR of 19.09%, reaching USD 386.58 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 113.74 billion
Estimated Year [2026] USD 135.25 billion
Forecast Year [2032] USD 386.58 billion
CAGR (%) 19.09%

A clear and compelling introduction to how therapeutic complexity, regulatory expectations, and supply resilience are redefining CMO and CRO strategic priorities worldwide

The contract manufacturing and contract research landscape is undergoing rapid evolution as therapeutic complexity, regulatory scrutiny, and commercial timelines converge to reshape strategic priorities. Outsourcing is no longer a transactional cost-saving exercise but a core enabler of innovation velocity, capacity scaling, and risk sharing across discovery, development, and commercialization. Increasingly sophisticated biologics, gene and cell therapies, and modular manufacturing approaches are driving demand for partners who can support integrated workflows from analytical testing through clinical supply and commercial fill-finish.

In addition, the industry is contending with amplified expectations around quality, traceability, and regulatory readiness. Sponsors and service providers must coordinate earlier and more closely to align development pathways, technology transfer, and validation strategies, thereby reducing time-to-patient while protecting product integrity. Simultaneously, heightened attention to environmental, social, and governance factors and to supply chain resilience is influencing procurement criteria and capital allocation decisions.

Consequently, successful organizations are investing in platform technologies, cross-functional governance, and strategic collaborations that enable flexible scale-up, accelerated clinical timelines, and predictable commercialization handoffs. This report begins by situating these forces and then explores specific structural shifts that will determine competitive advantage across service lines and geographies.

Identifying the converging technological, regulatory, and commercial forces that will fundamentally transform service delivery models and competitive advantage in the CMO and CRO sector

The landscape for contract manufacturing and research is being reshaped by several transformative shifts that operate in parallel and feed one another. First, therapeutic innovation is increasing technical complexity: the rise of cellular, gene, and advanced biologic modalities requires new process know-how, specialized facilities, and highly trained personnel. As a result, capacity investments are not simply about scale but about the ability to operate within tight quality and safety envelopes while accelerating iterative development cycles.

Second, technology adoption is changing operational models. Digitalization, advanced analytics, and modular automation enhance process control and enable predictive maintenance, but they also raise the bar for data integrity and interoperability across partners. Third, commercial and regulatory expectations are converging on earlier alignment between sponsors and providers, which incentivizes integrated service offerings spanning analytical, process development, and clinical supply. Fourth, capital constraints and the pursuit of faster time-to-revenue are encouraging strategic partnerships, joint ventures, and asset-light models that distribute risk while preserving strategic optionality.

These shifts collectively favor organizations that combine technical depth with flexible capacity, robust digital infrastructure, and the governance mechanisms to manage complex multi-stakeholder projects. In the months ahead, the ability to translate platform competencies into reproducible outcomes will determine which providers capture the most durable client relationships.

Examining how recent tariff policy shifts and trade dynamics are amplifying supply chain risk and compelling strategic realignment across outsourced pharmaceutical development and manufacturing

Policy changes affecting tariffs and trade flows have material implications for global manufacturing and the clinical supply chain, and the cumulative effects of tariff measures enacted or signaled in 2025 have amplified strategic reassessment across the industry. Increased import duties on active pharmaceutical ingredients, single-use components, and specialized equipment raise landed costs for outsourced production and can slightly elongate lead times due to shifted sourcing and customs clearance practices. In response, many sponsors and providers are reevaluating supplier footprints to balance cost, lead-time certainty, and regulatory compliance.

As a consequence, organizations are accelerating diversification strategies that include alternate sourcing, dual-sourcing arrangements, and regional capacity expansion to mitigate concentrated exposure. Nearshoring and onshoring initiatives have gained renewed attention where regulatory regimes and local incentives align to offset tariff-related cost pressures. Furthermore, procurement teams are increasingly incorporating total landed cost analyses, factoring in duties, insurance, transport, and potential regulatory retesting when selecting suppliers.

From an operational perspective, the tariff environment has underscored the importance of inventory strategy and demand forecasting. Sponsors reliant on critical inputs with constrained supplier bases are prioritizing safety-stock policies and strengthening contractual clauses around lead times and quality assurance. Ultimately, the tariff environment has accelerated strategic shifts toward resilient supply chains, localized capabilities, and deeper collaboration between sponsors and outsourced providers to preserve program timelines and product quality.

Comprehensive segmentation insights that map service modalities, product complexities, therapeutic applications, and end-user characteristics to strategic capability requirements and partnership models

A granular segmentation view illuminates where capabilities, regulatory demands, and commercial priorities intersect across service types, product classes, therapeutic applications, and end-user profiles. Service offerings include analytical workstreams, cell culture operations, clinical development support, fill-finish capabilities, formulation expertise, preclinical development, and process development; within clinical development, support spans Phase I through Phase III activities, each with distinct regulatory touchpoints and supply requirements. Product types bifurcate into large molecules and small molecules, where the large molecule category includes biologics and biosimilars, and biologics themselves encompass monoclonal antibodies, recombinant proteins, and vaccines. Small molecules cover generics and new chemical entities, with different speed-to-clinic dynamics and manufacturing footprints.

Applications further define technical requirements: cell therapies, comprising CAR T and stem cell approaches, demand closed systems, specialized cold-chain logistics, and stringent chain-of-custody controls, while gene therapies-divided into non-viral and viral vector platforms-require dedicated containment, vector production expertise, and unique analytical paradigms. Monoclonal antibodies include bispecific, conjugated, and naked variants, each with distinct purification and characterization needs. Recombinant proteins span enzymes, growth factors, and hormones, requiring specific expression systems and downstream processing strategies. Vaccines span inactivated, live attenuated, mRNA, and subunit formats, each bringing unique temperature, stability, and fill-finish challenges.

End users vary in scale and strategic intent: biotechnology companies range from large integrated organizations to small innovators with high experimental throughput; CROs may offer full-service capabilities or niche expertise; pharmaceutical companies are tiered by their global reach and internal capacity; and research institutions include academic centers and government laboratories focused on translational science. These distinctions influence procurement cycles, quality expectations, and partnership models. Taken together, segmentation reveals where investment in specialized capabilities, regulatory engagement, and commercial alignment will deliver the most value and competitive differentiation.

Regional strategic implications for facility investment, regulatory alignment, and partner selection across the Americas, EMEA, and Asia-Pacific ecosystems

Geographic context plays a decisive role in shaping capacity investment, regulatory strategy, and commercial outreach across the contract development and manufacturing ecosystem. The Americas present a mature environment characterized by established regulatory frameworks, a deep talent pool in biologics and advanced therapies, and significant private and public capital flowing into capacity expansion, particularly in regions with strong logistics and clinical ecosystems. This environment favors sponsors and providers that can leverage integrated networks spanning development, clinical trial execution, and commercial supply.

Europe, the Middle East, and Africa encompass a mosaic of regulatory regimes and incentive structures. Western European markets are notable for their high regulatory standards, strong academic-industry collaborations, and a robust presence of specialized service providers. The Middle East and select African markets are increasingly attractive for strategic partnerships and manufacturing hubs when paired with targeted incentives and investment in workforce development, although regulatory harmonization remains an implementation task in many jurisdictions.

Asia-Pacific combines rapid capacity expansion with divergent regulatory timelines and varied labor cost structures. Several economies in the region are investing heavily in state-of-the-art facilities and workforce training to capture a larger share of complex biologics and advanced therapy manufacturing. For sponsors, this regional mix requires nuanced partner selection that balances cost, speed, and regulatory alignment. Across all regions, cross-border regulatory coordination, logistics, and local talent development are key determinants of where sponsors elect to allocate development and manufacturing work.

Key observations on how technical depth, strategic partnerships, and digital-enabled operational excellence are redefining leadership in outsourced pharmaceutical development and manufacturing

Competitive dynamics among service providers are increasingly defined by depth of technical platforms, the ability to integrate across development stages, and the agility to support complex modalities. Leading firms are differentiating through investments in specialized facilities, proprietary analytical platforms, and automation that reduce variability and accelerate release testing. At the same time, a cohort of nimble niche providers is capitalizing on focused expertise-such as viral vector manufacturing, CAR T processing, or advanced fill-finish for mRNA products-by offering flexible, client-centric arrangements that appeal to emerging biotech sponsors.

Strategic partnerships and alliance models remain central to capability expansion. Sponsors and providers are pursuing co-investments, joint ventures, and long-term capacity reservations to secure access to scarce resources and to align incentives across development and commercialization phases. Operational excellence in quality systems, data integrity, and regulatory engagement is a non-negotiable differentiator; providers that demonstrate consistent compliance histories and transparent audit trails are winning multi-year engagements.

Additionally, service organizations that successfully marry digital platforms-enabling real-time analytics, batch tracking, and predictive maintenance-with process expertise are setting new expectations for responsiveness and transparency. Talent strategies are also evolving, with investments in cross-disciplinary teams that blend process science, regulatory affairs, and digital proficiency becoming essential to deliver complex programs reliably and at scale.

Actionable and prioritized recommendations for executives to strengthen operational resilience, regulatory readiness, and strategic partnerships across outsourced development and manufacturing

Industry leaders should adopt a set of pragmatic, prioritized actions to protect program timelines, enhance flexibility, and capture commercial advantage. First, sponsors and providers must accelerate investments in platform technologies and modular facility designs that enable rapid molecule transfer and scalable manufacturing without compromising quality. This includes targeted capital deployment for high-impact capabilities such as viral vector suites, closed-system cell therapy production, and advanced fill-finish lines that support temperature-sensitive formats.

Second, diversify sourcing and contractual arrangements to mitigate geopolitical and tariff-driven disruptions by establishing alternate suppliers, dual-sourcing critical inputs, and pursuing regionally balanced capacity. Third, strengthen regulatory engagement through early and frequent dialogue with authorities and adopt robust data management frameworks that support electronic submissions and traceability across partner networks. Fourth, prioritize talent development and retention strategies that build cross-functional competencies in process science, quality assurance, and digital operations, thereby reducing dependency on scarce external expertise.

Finally, formalize strategic collaborations using clear governance structures and shared KPIs to align incentives across multi-stakeholder projects. By taking these steps, organizations can reduce program risk, improve time-to-patient, and position themselves to capture the benefits of accelerating therapeutic innovation.

A rigorous and transparent multi-method research approach combining executive interviews, technical consultations, and secondary evidence to produce practitioner-focused insights and recommendations

This research synthesizes a multi-method approach designed to ensure robust, reproducible insights that reflect current industry dynamics and practitioner experience. The methodology combines primary qualitative interviews with senior executives across sponsor, provider, and institutional stakeholder groups, supplemented by technical consultations with process scientists, regulatory experts, and supply chain professionals to validate operational impacts. These conversations were structured to elicit practical perspectives on capacity constraints, technology adoption, and partnership models rather than to produce quantitative forecasts.

Secondary research drew on peer-reviewed literature, regulatory guidance documents, industry white papers, and company disclosures to contextualize primary findings and identify emergent patterns in investment and capability development. Data triangulation was employed to reconcile divergent viewpoints and to isolate consistent themes across geographies, service lines, and product modalities. Throughout, particular attention was given to methodological transparency, including documenting assumptions, interview sampling frames, and criteria used to classify service and product types.

Finally, iterative analyst workshops were convened to stress-test conclusions, ensuring that recommendations are actionable and grounded in real-world constraints. The approach emphasizes qualitative rigor and practitioner relevance to support decision-makers seeking to translate insight into operational plans.

A concise conclusion synthesizing how capability investment, regulatory alignment, and resilient partnerships will determine long-term competitiveness in outsourced therapeutics development

The cumulative picture is one of an industry at an inflection point where scientific innovation, operational complexity, and geopolitical dynamics intersect to redefine outsourcing strategy. Sponsors and providers that invest selectively in specialized capabilities, digital infrastructure, and resilient supply networks will be better positioned to de-risk development programs and accelerate patient access. Equally important is the adoption of partnership frameworks that align incentives and enable shared accountability for quality and timeline outcomes.

Operational resilience, regulatory engagement, and talent development emerge as the foundational pillars for success. Organizations that cultivate cross-functional teams, establish robust data governance, and pursue flexible sourcing arrangements can convert external shocks into manageable variances rather than catastrophic delays. As the industry continues to evolve, the ability to translate technical expertise into reproducible, auditable processes will determine which players sustain long-term partnerships and capture a disproportionate share of complex therapy programs.

In closing, the sector's trajectory favors those who combine scientific excellence with disciplined execution and strategic foresight. The decisions companies make today regarding capacity, technology, and collaborative models will shape competitive positioning for years to come.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biopharmaceutical CMO & CRO Market, by Product Type

  • 8.1. Large Molecule
    • 8.1.1. Biologics
      • 8.1.1.1. Monoclonal Antibodies
      • 8.1.1.2. Recombinant Proteins
      • 8.1.1.3. Vaccines
    • 8.1.2. Biosimilars
  • 8.2. Small Molecule
    • 8.2.1. Generics
    • 8.2.2. New Chemical Entities

9. Biopharmaceutical CMO & CRO Market, by Service Type

  • 9.1. Analytical
  • 9.2. Cell Culture
  • 9.3. Clinical Development
    • 9.3.1. Phase I
    • 9.3.2. Phase II
    • 9.3.3. Phase III
  • 9.4. Fill-Finish
  • 9.5. Formulation
  • 9.6. Preclinical Development
  • 9.7. Process Development

10. Biopharmaceutical CMO & CRO Market, by Therapeutic Area

  • 10.1. Oncology
  • 10.2. Infectious Diseases
  • 10.3. Cardiovascular
  • 10.4. Central Nervous System
  • 10.5. Immunology And Inflammation
  • 10.6. Respiratory
  • 10.7. Metabolic And Endocrine
  • 10.8. Rare Diseases

11. Biopharmaceutical CMO & CRO Market, by Application

  • 11.1. Cell Therapies
    • 11.1.1. CAR T
    • 11.1.2. Stem Cell
  • 11.2. Gene Therapies
    • 11.2.1. Non Viral
    • 11.2.2. Viral Vector
  • 11.3. Monoclonal Antibodies
    • 11.3.1. Bispecific
    • 11.3.2. Conjugated
    • 11.3.3. Naked
  • 11.4. Recombinant Proteins
    • 11.4.1. Enzymes
    • 11.4.2. Growth Factors
    • 11.4.3. Hormones
  • 11.5. Vaccines
    • 11.5.1. Inactivated
    • 11.5.2. Live Attenuated
    • 11.5.3. mRNA
    • 11.5.4. Subunit

12. Biopharmaceutical CMO & CRO Market, by End User

  • 12.1. Biotechnology Companies
    • 12.1.1. Large Biotech
    • 12.1.2. Small Biotech
  • 12.2. CROs
    • 12.2.1. Full Service
    • 12.2.2. Niche Service
  • 12.3. Pharmaceutical Companies
    • 12.3.1. Tier I
    • 12.3.2. Tier II
    • 12.3.3. Tier III
  • 12.4. Research Institutions
    • 12.4.1. Academia
    • 12.4.2. Government

13. Biopharmaceutical CMO & CRO Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Biopharmaceutical CMO & CRO Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biopharmaceutical CMO & CRO Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Biopharmaceutical CMO & CRO Market

17. China Biopharmaceutical CMO & CRO Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. AbbVie, Inc.
  • 18.7. arexel International Corporation
  • 18.8. Baxter International Inc.
  • 18.9. Boehringer Ingelheim Biopharmaceuticals GmbH
  • 18.10. Boehringer Ingelheim GmbH
  • 18.11. Catalent, Inc.
  • 18.12. Charles River Laboratories International, Inc.
  • 18.13. Eurofins Scientific Limited
  • 18.14. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • 18.15. ICON Plc
  • 18.16. KBI Biopharma, Inc.
  • 18.17. KEMWELL BIOPHARMA PRIVATE LIMITED
  • 18.18. Laboratory Corporation of America Holdings
  • 18.19. Lonza Group AG
  • 18.20. NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC
  • 18.21. Patheon Inc.
  • 18.22. Rentschler Biopharma SE
  • 18.23. Sterling Pharma Solutions

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOSIMILARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOSIMILARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENERICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENERICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENERICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NEW CHEMICAL ENTITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NEW CHEMICAL ENTITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NEW CHEMICAL ENTITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ANALYTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ANALYTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ANALYTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY FILL-FINISH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY FILL-FINISH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY FILL-FINISH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY IMMUNOLOGY AND INFLAMMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY IMMUNOLOGY AND INFLAMMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY IMMUNOLOGY AND INFLAMMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY METABOLIC AND ENDOCRINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY METABOLIC AND ENDOCRINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY METABOLIC AND ENDOCRINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CAR T, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CAR T, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CAR T, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY STEM CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY STEM CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY STEM CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NON VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NON VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NON VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BISPECIFIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BISPECIFIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BISPECIFIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CONJUGATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CONJUGATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CONJUGATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NAKED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NAKED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NAKED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY HORMONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY HORMONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY HORMONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY FULL SERVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY FULL SERVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY FULL SERVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NICHE SERVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NICHE SERVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NICHE SERVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY TIER I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY TIER I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY TIER I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY TIER II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY TIER II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY TIER II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY TIER III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY TIER III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY TIER III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ACADEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ACADEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ACADEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GOVERNMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GOVERNMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GOVERNMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 199. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 201. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 202. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 203. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 205. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 206. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 208. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 209. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 210. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 211. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 212. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 214. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, 2018-2032 (USD MILLION)
  • TABLE 215. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 216. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 222. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 224. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 228. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 230. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, 2018-2032 (USD MILLION)
  • TABLE 234. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 236. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 240. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 244. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 246. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 248. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 250. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 252. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, 2018-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 254. LATIN AMERICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY GENE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CROS, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 294. MIDDLE EAST BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY LARGE MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 296. MIDDLE EAST BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 298. MIDDLE EAST BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 20